CAS Registry Number 107133-36-8
Potassium Supplements and Potassium-Sparing Diuretics: Perindopril Tablets
may increase serum potassium because of its potential to decrease
aldosterone production. Use of potassium-sparing diuretics (spironolactone,
amiloride, triamterene and others), potassium supplements or other drugs
capable of increasing serum potassium (indomethacin, heparin, cyclosporine
and others) can increase the risk of hyperkalemia. Therefore, if concomitant
use of such agents is indicated, they should be given with caution and the
patient's serum potassium should be monitored frequently.
Lithium: Increased serum lithium and symptoms of lithium toxicity have been
reported in patients receiving concomitant lithium and ACE inhibitor
therapy. These drugs should be coadministered with caution and frequent
monitoring of serum lithium concentration is recommended. Use of a diuretic
may further increase the risk of lithium toxicity.
Gold: Nitritoid reactions (symptoms include facial flushing, nausea,
vomiting and hypotension) have been reported rarely in patients on therapy
with injectable gold (sodium aurothiomalate) and concomitant ACE Inhibitor
therapy including Perindopril.
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma
digoxin concentrations when coadministered with Perindopril Tablets, but an
effect of digoxin on the plasma concentration of perindopril/perindoprilat
has not been excluded.
Gentamicin: Animal data have suggested the possibility of interaction
between perindopril and gentamicin. However, this has not been investigated
in human studies. Coadministration of both drugs should proceed with